Camoteskimab

CAT: 0804-HY-P99491-01Size: 1 mgDry Ice: YesHazardous: No
CAT#:0804-HY-P99491-01Size:1 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Camoteskimab (AVTX-007) is an anti-IL-18 monoclonal antibody with fully humanized, high-affinity. Camoteskimab specifically binds IL-18 and blocks the interaction of IL-18 with its receptor. Camoteskimab is promising for research of cardiovascular diseases and autoinflammatory diseases, including adult-onset Still’s disease (AOSD) and multiple myeloma[1][2][3][4][5].
CAS Number
[2492472-82-7]
Product Name Alternative
AVTX-007; CERC-007; MEDI 2338
UNSPSC
12352203
Target
Interleukin Related
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/camoteskimab.html
Purity
99.0
Solubility
10 mM in DMSO
Smiles
[Camoteskimab]
Molecular Weight
(146.34 kDa)
References & Citations
[1]Paola Galozzi, et al. Progress in Biological Therapies for Adult-Onset Still's Disease. Biologics. 2022 Apr 21;16:21-34. |[2]Brennan S, et al. Genetically Predicted IL-18 Inhibition and Risk of Cardiovascular Events: A Mendelian Randomization Study[J]. medRxiv, 2024: 2024.07. 01.24309808.|[3]Bindoli S, et al. Adult-Onset Still's Disease (AOSD) : Advances in Understanding Pathophysiology, Genetics and Emerging Treatment Options. Drugs. 2024 Mar;84 (3) :257-274.|[4]Macovei LA, et al. Adult-Onset Still's Disease-A Complex Disease, a Challenging Treatment. Int J Mol Sci. 2022 Oct 24;23 (21) :12810.|[5]Galozzi P, et al. Progress in Biological Therapies for Adult-Onset Still's Disease. Biologics. 2022 Apr 21;16:21-34.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 2

Related Products

CatalogName

Popular Products